M

Monte Rosa Therapeutics

Develops targeted protein degraders for therapy

Director Program Management 1 and 1 Full Life Cycle

Program ManagementPosted on Nov 5
Full-timeBoston, MA, USA$150k - $225kIn-person

About the Job

Requirements

  • At least 12 years of experience in biotechnology or pharmaceutical drug development.
  • At least 8 years of program or project management experience leading cross-functional development teams.
  • Demonstrated experience advancing immunology and/or inflammation assets through Phase 2 and Phase 3 development.
  • Experience preparing for and supporting major regulatory interactions, such as End-of-Phase 2 meetings and NDA/BLA submissions.
  • Experience operating in small-to-mid-sized biotechnology environments requiring agility and hands-on leadership.
  • A bachelor's degree is required.
  • Strong understanding of immunology and inflammation biology, clinical endpoints, biomarker strategy, and regulatory considerations.
  • Deep knowledge of end-to-end drug development within a resource-conscious biotechnology setting.
  • Demonstrated ability to lead through ambiguity and adapt strategy as data emerge.
  • Proven success influencing senior stakeholders in a highly matrixed environment.
  • Expertise in integrated planning, risk management, and scenario modeling.
  • Ability to communicate complex scientific and operational topics clearly and concisely to executive audiences.
  • Proficiency with modern project management and collaboration tools, including Smartsheet, MS Project, and Teams.
  • Ability to manage multiple interdependent workstreams simultaneously.
  • Strong conflict resolution skills and ability to build trust across scientific and operational teams.
  • Comfort operating with urgency, limited infrastructure, and evolving priorities typical of innovative biotechnology companies.

Responsibilities

  • Serve as a strategic and operational lead for one or more immunology and inflammation programs, ensuring alignment between clinical strategy, translational insights, and regulatory pathways.
  • Develop and maintain integrated, cross-functional development plans across clinical, regulatory, CMC, manufacturing, and translational functions.
  • Lead scenario-planning exercises to evaluate alternative development pathways, indication sequencing, acceleration opportunities, and capital-efficient trade-offs.
  • Continuously pressure-test timelines and critical paths, proactively identifying opportunities to streamline execution without compromising quality.
  • Establish proactive risk identification and mitigation frameworks tailored to immunology and inflammation programs, including biomarker risk, patient heterogeneity, regulatory complexity, and competitive landscape shifts.
  • Lead high-quality risk discussions at the Global Program Team level and escalate high-impact issues in a timely manner.
  • Develop contingency strategies for clinical, manufacturing, or regulatory inflection points.
  • Monitor program-level budget and resource health in alignment with corporate priorities.
  • Ensure clarity of functional accountabilities and decision rights in a lean, matrixed biotechnology structure.
  • Partner with functional leaders during long-range planning and portfolio prioritization exercises.
  • Build and maintain practical, real-time tracking tools, such as Smartsheet dashboards, integrated timelines, and risk logs, to enable rapid visibility and decision-making.
  • Prepare concise, executive-ready materials that distill complex scientific and operational issues into clear recommendations.
  • Lead continuous improvement initiatives within Program Management to enhance agility, transparency, and execution discipline.

Desired Qualifications

  • An advanced degree (MS, PhD, or MBA) is strongly preferred.
  • PMP certification is desirable but not required.

About the Company

Monte Rosa Therapeutics

Develops targeted protein degraders for therapy

Monte Rosa Therapeutics develops molecular glue degraders (MGDs) to treat cancer and autoimmune/inflammatory diseases using its QuEEN discovery engine, a platform that fuses AI-guided chemistry, proteomics, and structural biology to design MGDs. MGDs work by bringing a target protein together with an E3 ligase, tagging the protein for destruction by the cell's proteasome rather than just inhibiting it. The company distinguishes itself with the QuEEN platform, partnerships with Roche and Novartis for joint development and funding, and a portfolio that includes MRT-2359, MRT-6160, and MRT-8102 as clinical-stage programs. Its goal is to discover, develop, and commercialize MGDs, grow its pipeline, and create value through collaborations, upfront payments, milestones, and royalties while delivering treatments for patients with serious diseases.

Company size
201-500
Company stage
IPO
Headquarters
Boston, MA
Founded
2018

Recently Posted Jobs

Explore more opportunities at Monte Rosa Therapeutics

See more jobs